Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-11
- 2018-10
- 2018-07
-
Herein we explored by docking studies the effectiveness of
2021-06-07

Herein, we explored by docking studies the effectiveness of replacing the dimethyl substitution at C (6) of dihydrotriazine with a folded azaspiro-containing substituent, along with the introduction of differently substituted phenyl- and benzyl-rings or alkyl chains, linked at the position 1 of the
-
glutathione s-transferase Primary human GBM neurospheres exp
2021-06-07

Primary human GBM neurospheres expressed high levels of the metabolic enzyme fatty acyl-CoA synthetase VL3 (ACSVL3) that were associated with CSCs self-renewal and tumorigenic capacity. ACSVL3 knockdown significantly decreased ALDH levels, indicating its contribution to cell metabolism and maintenan
-
Interestingly some drugs have been shown to be effective
2021-06-07

Interestingly, some drugs have been shown to be effective in the regulation of cytokine production (such as IL-2, IL-10, IL-27, IL-35, IL-37 and transforming growth factor-β, TGF-β) and, therefore, having a key role in the management of certain inflammatory-based clinical conditions (Banchereau et a
-
Several highly potent CysLT receptor antagonists with large
2021-06-07

Several highly potent CysLT1 receptor antagonists with large structural serine protease have been developed. Beyond antagonists with structures analogous to cysteinyl leukotrienes, other subclasses comprise: (a) hydroxyacetophenones, (b) indoles and indazoles, (c) quinolines, benzothiazoles, and thi
-
In the course of our program
2021-06-07

In the course of our program, which was aimed at developing CRTH2 antagonists for the treatment of allergic diseases, we have been pursuing a new class of potent and selective CRTH2 antagonist lead based on the structures of CRTH2 antagonists known to date (, , ). Using a fused 6–6-membered ring sys
-
CXCL mediated cell migration is facilitated by
2021-06-07

CXCL16 mediated cell migration is facilitated by the interaction of soluble CXCL16 with CXCR6, expressed predominantly on the cell surface of CD4+ Th1 cells, cancer infiltrating lymphocytes and platelets (Borst et al., 2012, Kim et al., 2001, Liao et al., 1997, Wilbanks et al., 2001). CXCR6 is invol
-
br Results and discussion br Conclusion br Experimental
2021-06-07

Results and discussion Conclusion Experimental section Pharmacological studies Introduction Survival analysis is a set of statistical methods that aim at modeling the relationship between a set of predictor variables and an outcome variable and, in particular, prediction of the time w
-
Haggar et al reported the synthesis
2021-06-07

Haggar et al. reported the synthesis of two new series of 8-(2-imino/oxo/thioxo pyrimidin-4-yl)-4-methyl-6-nitro-2-oxo-2H-chromen-7-yl benzoates 56 (X=O, S, NH) and 8-(pyrazol-3-yl)-4-methyl-6-nitro-2-oxo-2H-chromen-7-yl benzoates 57 [Y=C(O)CH3, 2,4-(NO2)2C6H3]. The 8-acetyl-4-methyl-6-nitro-2-oxo-2
-
WM refers to the storage
2021-06-07

WM refers to the storage of information in the context of processing, and coordination of elements into new structures (Oberauer, Süß, Wilhelm, & Wittman, 2003). Concerning the impact of WM on ISV facets, a strong negative association between WM and ex-Gaussian tau, suggesting that improved WM perfo
-
AON successfully alleviated the myotonic phenotype
2021-06-07

AON successfully alleviated the myotonic phenotype in DM model mice [18], [23]. To screen for an optimal AON sequence, we used 25-mer phosphorothioate 2′ O-methyl RNA molecules that covered the exon 6B or exon 7A. Unexpectedly, AON 7A (+63−8) which covers the boundary of intron 7A and exon 7A enhanc
-
Although it remains an unsettled issue evidence favors that
2021-06-07

Although it remains an unsettled issue, evidence favors that the endothelin ETA ABT-199 australia may play a more important pathological role. While both endothelin ETA and ETB receptors are found in most tissues, endothelin ETA receptor is the predominant receptor responsible for the vasoconstricti
-
To our knowledge immunohistochemical analysis for proGRP was
2021-06-07

To our knowledge, immunohistochemical analysis for proGRP was done in 5 cases [9], [10], [17], [18]. Takagi-Takahashi et al. reported that the tumor Butyrolactone 3 were positive for proGRP in one case [9]. Yamaguchi et al. also showed that tumor cells in two patients of ES/PNET with elevated serum
-
To our knowledge this is the first report of
2021-06-05

To our knowledge, this is the first report of an oncocytoma expressing alpha-enolase or causing autoimmune retinopathy and optic neuropathy. Although generally considered benign, oncocytomas have rarely been associated with paraneoplastic syndromes, including tumor-induced hypertension, erythrocytos
-
br Regulation of cadherin switching The downregulation of E
2021-06-05

Regulation of cadherin switching The downregulation of E-cadherin during cadherin switching is induced by multiple mechanisms, including methylation of the E-cadherin promoter and signaling pathways that activate E-cadherin-suppressing transcription factors [[61], [62], [63]]. During the progress
-
Imatinib STI is a first
2021-06-05

Imatinib (STI-571) is a first-line tyrosine kinase inhibitor (TKI) targeted at breakpoint cluster region-Abelson kinase (ABL) for the treatment of chronic myeloid leukemia (CML) [26]. As a type II inhibitor, imatinib achieves significant selectivity by binding to an inactive DFG-out conformation (DF
16734 records 679/1116 page Previous Next First page 上5页 676677678679680 下5页 Last page